Data Sheet 3_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

“…Background<p>Chronic coronary syndromes (CCS) is a common clinical condition that increases the risk of cardiovascular events at any time. Tongxinluo capsules (TXL) are widely used in China for treating CCS.…”

Data Sheet 4_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

“…Background<p>Chronic coronary syndromes (CCS) is a common clinical condition that increases the risk of cardiovascular events at any time. Tongxinluo capsules (TXL) are widely used in China for treating CCS.…”

Data Sheet 1_Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning.zip by Shuxian Pan (8868356)

“…The impact of influencing factors on irAEs (immune-related adverse events) was validated using Decision Curve Analysis (DCA). …”

CCDC66 localizes to the axoneme and regulates primary cilium stability but not cilia formation in IMCD3 cells. by Jovana Deretic (13113617)

“…The mean cilia length in CCDC66-depleted cells decreased to 0.67-fold compared to the mean control length. …”

Table 1_Effect of ticagrelor combined with metoprolol extended-release tablets on cardiac function and clinical prognosis in elderly patients with acute coronary syndrome after per... by Lili Wang (104605)

“…The incidence of adverse prognostic events in the OG was significantly lower at 8.89%, compared to 37.78% in the CG (P < 0.05).…”

Supplementary file 1_Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness.docx by Omar Z. Ameer (8900039)

“…Clinical trials have demonstrated significant reductions in asthma exacerbation rates, improvements in forced expiratory volume in one second (FEV₁), and decreased oral corticosteroid (OCS) dependence in adults and children with moderate-to-severe asthma. …”

Data Sheet 1_Comparison of intravascular imaging, physiological assessment and angiography for coronary revascularization in acute coronary syndrome: a systematic review and networ... by Xuan-Yan Liu (19362096)

“…The primary outcome for this research was major adverse cardiovascular events (MACE) occurrences. Each PCI strategy was ranked as per the risk ratio (RR) at the 95% confidence interval (95% CI) for developing MACE.…”

Supplementary file 1_Therapeutic efficacy and safety of Xuebijing in traumatic brain injury: systematic review and meta-analysis.docx by Yihan Sun (3432287)

“…No significant increase in adverse drug events (ADEs) was observed (RR = 1.32, 95% CI 0.58–2.96). …”

Supplementary file 2_Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness.docx by Omar Z. Ameer (8900039)

“…Clinical trials have demonstrated significant reductions in asthma exacerbation rates, improvements in forced expiratory volume in one second (FEV₁), and decreased oral corticosteroid (OCS) dependence in adults and children with moderate-to-severe asthma. …”

Data Sheet 1_Administration of anticoagulation strategies for portal vein thrombosis in cirrhosis: network meta-analysis.docx by Hui-Jun Li (1480486)

“…Warfarin and TIPS were recommended for reducing the frequency of bleeding events, while LMWH plus warfarin and DOACs proved to be most effective in decreasing the rate of major bleeding events. …”

Data Sheet 1_Impact of mini-dose dexmedetomidine supplemented analgesia on sleep structure in patients at high risk of obstructive sleep apnea: a pilot trial.docx by Pei Sun (115160)

“…Adverse events were similar between groups.</p>Conclusion<p>Among patients at high risk of OSA who underwent noncardiac surgery, mini-dose dexmedetomidine supplemented analgesia may improve sleep quality without increasing adverse events.…”

Data Sheet 1_Hypocomplementemia dynamics during tocilizumab therapy in systemic juvenile idiopathic arthritis: a retrospective longitudinal study.xlsx by Jiayun Ling (15249289)

“…Notably, C3 remained significantly correlated at week 48 (r = 0.513, P = 0.025). …”

Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Results<p>All planned treatments were administered, and there were no serious adverse events. Four patients had no significant clinical changes. …”

Data Sheet 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf by figshare admin frontiersin (4545187)

“…</p>Results<p>All planned treatments were administered, and there were no serious adverse events. Four patients had no significant clinical changes. …”

Data Sheet 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf by Øystein Fluge (200378)

“…</p>Results<p>All planned treatments were administered, and there were no serious adverse events. Four patients had no significant clinical changes. …”

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Results<p>All planned treatments were administered, and there were no serious adverse events. Four patients had no significant clinical changes. …”

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Results<p>All planned treatments were administered, and there were no serious adverse events. Four patients had no significant clinical changes. …”

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

“…</p>Results<p>All planned treatments were administered, and there were no serious adverse events. Four patients had no significant clinical changes. …”

Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Results<p>All planned treatments were administered, and there were no serious adverse events. Four patients had no significant clinical changes. …”

Data Sheet 1_Brain injury, endocrine disruption, and immune dysregulation in HIV-positive men who have sex with men with late HIV diagnosis.docx by Yihui He (2936874)

“…These imaging findings were significantly correlated with endocrine, immune, and clinical variables.…”